Advertisement

Silence Therapeutics appoints Chief Medical Officer, shares rise

Silence Therapeutics has unveiled Michael Khan as the company's new Chief Medical Officer.

Silence Therapeutics has unveiled Michael Khan as the company's new Chief Medical Officer.

He will oversee the phase II study on ATU027 for cancer and aid in the expansion of the private biotechnology company's clinical pipelines in oncology and acute lung injury.

Khan is a consultant endocrinologist at University Hospitals of Coventry and Warwickshire. He is also an associate professor of medicine at the University of Warwick.

Advertisement - Article continues below

Last September he became a director and chief medical adviser at Silence Therapeutics, which develops systematic RNA interference therapeutics for the treatment of cancer and other diseases.

"These are very exciting times for Silence Therapeutics, with one oncology drug advancing to phase II," he said in a statement.

"Moreover, with a range of new indications in the pipeline, I am really happy to be a part of this dynamic new enterprise."

Ali Mortazavi, director of Corporate Strategy, added: "I'm delighted Mike has decided to devote more time to us. Next year will be pivotal for Silence after so many years spent preparing for phase II trials."

Shares jumped 9.71% to 4.80p at 12:39 Wednesday.

RD

Advertisement
Advertisement

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

OBR: UK house prices could fall by 12% next year
House prices

OBR: UK house prices could fall by 12% next year

The Office for Budget Responsibility says UK house prices could fall by as much as 12% next year. John Stepek looks at how likely that is.
14 Jul 2020
Three ideas for Lloyds Bank's new boss
UK stockmarkets

Three ideas for Lloyds Bank's new boss

The Black Horse needs whipping into shape. A change at the top provides a great opportunity, says Matthew Lynn.
12 Jul 2020
We’re spending more than at any time since World War II – how will we pay it back?
UK Economy

We’re spending more than at any time since World War II – how will we pay it back?

With the UK spending vast sums on stimulus measures, this year’s budget deficit will be greater than at any time since World War II. The big question,…
14 Jul 2020